Welfaszo-Kit Tablet is a combination pharmaceutical formulation containing Fluconazole 150 mg, Azithromycin 1000 mg, and Secnidazole 1000 mg, designed for the treatment of mixed infections involving fungal and bacterial pathogens, as well as protozoal infections. Fluconazole, a triazole antifungal agent, inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis and thereby compromising fungal cell membrane integrity. Azithromycin, a macrolide antibiotic, exerts its antibacterial effect by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and exhibiting broad-spectrum activity against Gram-positive and certain Gram-negative bacteria. Secnidazole, a nitroimidazole derivative, is effective against anaerobic protozoa and bacteria by causing DNA strand breakage and inhibiting nucleic acid synthesis. This combination is particularly useful in managing mixed infections such as bacterial vaginosis, trichomoniasis, and candidiasis, where polymicrobial involvement is common. Welfaszo-Kit should be administered under medical supervision, with dosage and duration tailored to the specific infection and patient condition. Caution is advised in patients with hepatic or renal impairment, and potential drug interactions should be considered. Side effects may include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, hepatotoxicity. This combination therapy offers a comprehensive approach to complex infections requiring simultaneous antifungal, antibacterial, and antiprotozoal treatment.